mtm laboratories - Gilde Healthcare

mtm laboratories


Heidelberg, Germany

Diagnosic Tests in Cervical Cancer
Since: 2009
Exit: 2011

mtm laboratories manufactures and commercializes in-vitro diagnostic tests for the analysis of cervical cancer. Worldwide, cervical cancer is the second most common cancer in women. mtm’s CINtec® technology detects a specific cellular biomarker (p16INK4a) and offers the potential for highly specific and accurate diagnosis of early-stage cervical cancer, even if it is without symptoms.

Since Gilde invested in mtm laboratories, the German company has clinically validated its diagnostic products and more than doubled its sales. mtm laboratories was acquired by Roche in 2011.

More mtm laboratories news

mtm laboratories acquired for EUR 190 million

Study of CINtec® PLUS in the management of Pap negative but HPV positive women published

mtm laboratories Extends Series C Financing Round by EUR 7 Million ($9.7 Million)

MTM Laboratories – p16 Immuno-cytochemistry shows superior clinical performance to HPV testing

mtm’s CINtec® PLUS, delivers new solution to manage Pap negative but HPV positive women

mtm laboratories Announces the European Launch of CINtec(R) PLUS

MTM LABORATORIES – CINtec® p16 Histology test increases accuracy in diagnosing

GILDE HEALTHCARE II invests in mtm laboratories AG